A Phase 2 interventional study of Fluticasone and Comparator: Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.
Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 56th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 2, and was the 7th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 40+
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 95 across the 59 interventional studies. Of the 48 that completed or were terminated, 24 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 26th largest by enrollment, is one of 2 that started in 2006, is one of 18 in phase 2, and was the 3rd registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing fluticasone in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: drug, crossing over to Pbo comparator
Drug: Fluticasone
Arm 2: Pbo comparator, crossing over to drug
Drug: Fluticasone · Drug: Comparator: Placebo
fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Standardized Dyspnea Score at Isotime During Exercise
Difference in standardized dyspnea rating at isotime during constant load exercise in patients with COPD between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period. Isotime is the duration of the shortest exercise test on all treatment days (or the longest exercise time point common to all constant-load exercise tests). The standardized dyspnea score will be measured with the modified 10-point Borg Scale (0 \[Best\] - 10 \[Worst\] ).
Time frame: 2 Weeks
Exercise Endurance Time
Difference in exercise endurance time between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.
Time frame: 2 Weeks
Patients were recruited from 1 center in Canada. Patient screening began 14-Dec-2006 and the first patient was randomized on 16-Feb-2007. Last patient last visit for the study was 31-Jul-2009.
| Milestone | Fluticasone Propionate Then Placebo | Placebo Then Fluticasone Propionate |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Fluticasone Propionate Then Placebo | Placebo Then Fluticasone Propionate |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Fluticasone Propionate Then Placebo | Placebo Then Fluticasone Propionate |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
Difference in standardized dyspnea rating at isotime during constant load exercise in patients with COPD between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period. Isotime is the duration of the shortest exercise test on all treatment days (or the longest exercise time point common to all constant-load exercise tests). The standardized dyspnea score will be measured with the modified 10-point Borg Scale (0 \[Best\] - 10 \[Worst\] ).
| Units on a Scale | Fluticasone Propionate | Placebo |
|---|---|---|
| Standardized Dyspnea Score at Isotime During Exercise | 3.58 ± 2.14 | 4.50 ± 2.18 |
Difference in exercise endurance time between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.
| Minutes | Fluticasone Propionate | Placebo |
|---|---|---|
| Exercise Endurance Time | 12.92 ± 10.52 | 9.75 ± 6.93 |
Collected over Screening to 14 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Propionate | — | 0/12 (0%) | 5/12 (41.7%) |
| Placebo | — | 0/12 (0%) | 2/12 (16.7%) |
| Event | Fluticasone Propionate | Placebo |
|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/12 | 2/12 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 1/12 | 0/12 |
| Gastrointestinal InfectionInfections and infestations | 1/12 | 0/12 |
| NasopharyngitisInfections and infestations | 1/12 | 0/12 |
| PneumoniaInfections and infestations | 1/12 | 0/12 |
| Viral InfectionInfections and infestations | 1/12 | 0/12 |
| Tooth FractureInjury, poisoning and procedural complications | 1/12 | 0/12 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 |
| Upper Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 67.9 ± 6.7 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 4 |
| Male | 8 |
| Exercise endurance time at the beginning of Fluticasone Propionate(Minutes) | Entire Study Population |
|---|---|
| Mean | 9.67 ± 7.88 |
| Exercise endurance time at the beginning of placebo treatment(Minutes) | Entire Study Population |
|---|---|
| Mean | 9.42 ± 6.73 |
| Standardized Dyspnea Score at isotime at the beginning of Fluticasone(Units on a Scale) | Entire Study Population |
|---|---|
| Mean | 4.50 ± 1.87 |
| Standardized Dyspnea Score at isotime at the beginning of placebo(Units on a Scale) | Entire Study Population |
|---|---|
| Mean | 4.75 ± 2.13 |
No study locations are listed for this record.
The record gives a start of Dec 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Pulmonary Disease, Chronic Obstructive →